Lisa von Moltke Joins Zenas BioPharma as CMO and Research Head
Leadership Expansion at Zenas BioPharma
In a significant step forward for Zenas BioPharma, the company has appointed Dr. Lisa von Moltke, a seasoned professional with over 30 years of experience in drug development, as its new Head of Research and Development and Chief Medical Officer.
Dr. von Moltke's diverse background spans various therapeutic areas, notably in autoimmune diseases. Her extensive experience in both large and emerging biopharmaceutical companies equips her with a remarkable understanding of the clinical development landscape, which is crucial as Zenas advances its innovative treatments.
A Commitment to Transformative Therapies
Zenas BioPharma, known for its commitment to developing therapies that make a real difference in the lives of patients, is particularly focused on the drug obexelimab, which is currently undergoing Phase 2 and Phase 3 clinical trials. Lonnie Moulder, the Founder and CEO of Zenas, expressed excitement about Dr. von Moltke's appointment, highlighting her proven leadership and successful history in overseeing the development of multiple products.
“It is an exciting time to join Zenas. I am eager to help the company achieve its objectives and bring obexelimab to patients with autoimmune diseases throughout the world,” said Dr. von Moltke. Her confidence in obexelimab's unique mechanism, which allows it to inhibit B cell activity without completely depleting them, speaks to its potential in addressing complex autoimmune conditions effectively.
Dr. von Moltke’s Notable Career
Before joining Zenas, Dr. von Moltke held the position of Chief Medical Officer at Seres Therapeutics, leading clinical development initiatives. Her previous roles include significant leadership positions at Alkermes, Inc., and Sanofi/Genzyme Corporation, where she honed her expertise in clinical pharmacology.
Her career has been marked by pivotal contributions to clinical advancement and an academic background in pharmacology that further solidifies her qualifications. Dr. von Moltke has also been actively involved in professional organizations, including serving as President of the American College of Clinical Pharmacology.
About Zenas BioPharma, Inc.
Zenas BioPharma stands at the forefront of biopharmaceutical innovation, focusing on the development of therapies aimed at autoimmune diseases. The company's strategic approach involves leveraging the expertise of its leadership team to discover and develop impactful product candidates globally.
Obexelimab, Zenas’ lead product candidate, represents a breakthrough in therapeutic options for diseases such as IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. This bifunctional monoclonal antibody has a unique design that targets the B cell lineage, inhibiting the activity that contributes to many autoimmune diseases without causing complete depletion of these vital cells.
Contact Information
If you wish to learn more about Zenas BioPharma or have inquiries, please reach out:
Investor Contact:
Matthew Osborne
Investor Relations and Corporate Communications
Matt.osborne@zenasbio.com
Media Contact:
Argot Partners
Zenas@argotpartners.com
Frequently Asked Questions
Who is the new Chief Medical Officer of Zenas BioPharma?
The new Chief Medical Officer is Dr. Lisa von Moltke, who has over 30 years of experience in drug development.
What will Dr. von Moltke focus on in her new role?
Dr. von Moltke will focus on advancing the clinical trials of obexelimab and leading the research and development efforts to impact autoimmune diseases.
What is obexelimab?
Obexelimab is Zenas’ lead product candidate, designed to inhibit B cell activity in autoimmune diseases without depleting them.
What experience does Dr. von Moltke bring to Zenas?
Dr. von Moltke brings extensive leadership experience from prior roles at Seres Therapeutics, Alkermes, and Sanofi/Genzyme, among others.
How can I contact Zenas BioPharma?
You can contact Zenas BioPharma through their investor relations email or media contact provided above in the article.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
